Corticosterone modulates auditory gating in mouse

Christina R MAXWELL; Richard S EHRLICHMAN; Yuling Liang; David R GETTES; Dwight L EVANS; Stephen J KANES; Ted ABEL; Jonathan KARP; Steven J SIEGEL

doi:10.1038/sj.npp.1300879

Back

Corticosterone modulates auditory gating in mouse

Journal article

Open access

Peer reviewed

Corticosterone modulates auditory gating in mouse

Christina R MAXWELL, Richard S EHRLICHMAN, Yuling Liang, David R GETTES, Dwight L EVANS, Stephen J KANES, Ted ABEL, Jonathan KARP and Steven J SIEGEL

Neuropsychopharmacology (New York, N.Y.), Vol.31(5), pp.897-903

2006

DOI: 10.1038/sj.npp.1300879

PMID: 16123740

Files and links (1)

url

https://doi.org/10.1038/sj.npp.1300879View

Published (Version of record) Open Access

Abstract

Previous studies suggest that circulating glucocorticoids may influence the encoding and processing of sensory stimuli. The current study investigated this hypothesis by measuring the generation (amplitude), gating (recovery cycle), and sensitivity (intensity function) of auditory evoked responses in C57BL/6 mice treated with chronic corticosterone (0, 1, 5, 15, or 30 mg/kg/day for 14 days). We found that low-dose corticosterone (5 but not 1 mg/kg/day) enhanced the amplitude and improved gating of evoked potentials without affecting the intensity function. In comparison, higher doses (15 and 30 mg/kg/day) decreased the amplitude and impaired gating of evoked potentials, also without altering the stimulus intensity function. At all doses, lower amplitudes of evoked potentials were significantly correlated with higher circulating corticosterone levels. These data highlight the need to consider serum glucocorticoid levels when assessing human disease states associated with aberrations of information processing such as schizophrenia and depression.

Biological and medical sciences

Medical sciences

Details

Title: Subtitle: Corticosterone modulates auditory gating in mouse
Creators: Christina R MAXWELL - Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Richard S EHRLICHMAN - Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Yuling Liang - Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
David R GETTES - Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Dwight L EVANS - Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Stephen J KANES - Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Ted ABEL - Department of Biology, University of Pennsylvania, Philadelphia, PA, United States
Jonathan KARP - Department of Biology, Rider University, Lawrenceville, NJ, United States
Steven J SIEGEL - Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States
Resource Type: Journal article
Publication Details: Neuropsychopharmacology (New York, N.Y.), Vol.31(5), pp.897-903
Publisher: Nature Publishing; New York, NY
DOI: 10.1038/sj.npp.1300879
PMID: 16123740
ISSN: 0893-133X
eISSN: 1740-634X
Language: English
Date published: 2006
Academic Unit: Molecular Physiology and Biophysics; Psychiatry; Psychological and Brain Sciences; Iowa Neuroscience Institute; Neuroscience and Pharmacology; Biochemistry and Molecular Biology
Record Identifier: 9984065833002771

Metrics

27 Record Views

26 Times Cited - Web of Science